Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Bioxcel Therapeutics Inc (BTAI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care FinancialNewsMedia - Tue Dec 17, 8:10AM CST

USA News Group Commentary Issued on behalf of Avant Technologies Inc. Vancouver, BC – December 17, 2024 – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming...

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering GlobeNewswire - Fri Nov 22, 7:16AM CST

BioXcel Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants Quiver Quantitative, Inc. - Fri Nov 22, 1:52AM CST

BioXcel Therapeutics announces an underwritten public offering of common stock and warrants to fund clinical trials and operations.Quiver AI SummaryBioXcel Therapeutics, Inc. has announced the launch of...

BioXcel Therapeutics Announces Proposed Public Offering GlobeNewswire - Thu Nov 21, 3:47PM CST

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results GlobeNewswire - Thu Nov 14, 6:00AM CST

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia GlobeNewswire - Tue Nov 12, 6:00AM CST

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 GlobeNewswire - Fri Nov 8, 6:00AM CST

BioXcel Therapeutics to Present at ThinkEquity Conference GlobeNewswire - Tue Oct 29, 6:00AM CDT

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder GlobeNewswire - Tue Oct 15, 6:00AM CDT

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies FinancialNewsMedia - Wed Feb 14, 7:31AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END